Evaluation of the effect of premedication in controlling acute complications of intravenous immunoglobulin injection

Evaluation and comparison of the effect of premedication (Methylprednisolone and Naproxen) with placebo in controlling acute complications of IVIG injection in patients with a diagnosis of neurological disease

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210206050268N1

Enrollment

Registered

2022-02-05

Start date

2022-01-05

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

premedication use for intravenous immunoglobulin administration. Adverse effect of immunoglobulin

Interventions

Intervention 1: Intervention group: tablet Naproxen 500 mg 30 minutes before intravenous immunoglobulin injection. Intervention 2: Intervention group: 1 mg/kg Methylprednisolone intravenous 30 minute

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients with a diagnosis of neurological disease, including myasthenia gravis, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), etc., who are candidates for IVIG will be included in the study.

Exclusion criteria

Exclusion criteria: The patient's unwillingness to participate in the study

Design outcomes

Primary

Measure	Time frame
Complications of intravenous immunoglobulin injection based on checklist. Timepoint: Evaluation of complications one and six hours after injection. Method of measurement: checklist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNafiseh sadat Mansouri tehrani

Esfahan University of Medical Sciences

nm.9311@yahoo.com+98 31 3233 0676

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026